Department of Clinical Laboratory, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Cancer Research Institute, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, Zhejiang, China.
Biomed Res Int. 2019 Aug 14;2019:2702719. doi: 10.1155/2019/2702719. eCollection 2019.
In esophageal squamous cell carcinoma, an elevated preoperative absolute monocyte count (Pre-AMC) is reported to be a predictor of survival, but the clinical application of postoperative absolute monocyte count change (AMCc) remains unknown. The present study was designed to investigate the prognostic value of AMCc in ESCC. 686 patients of ESCC after radical surgery without preoperative adjuvant therapy were enrolled. The Pre-AMC and AMCc were recorded within one week before the operation and one week after surgery. We considered the median of Pre-AMC as the optimal cut-off value to evaluate the relationship between Pre-AMC and patient survival. AMCc was defined as AMCc increased (higher than Pre-AMC) and AMCc decreased (lower than Pre-AMC). Demographic and clinical characteristics, disease-free survival (DFS), and overall survival (OS) were statistically analyzed. Multivariate analysis revealed that AMCc was a better independent prognostic factor for both OS (P = 0.002, HR = 0.614, 95% CI 0.450-0.837) and DFS (P = 0.023, HR = 0.656, 95% CI 0.456-0.943) than Pre-AMC which was only an independent prognostic factor for OS (P = 0.033, HR = 2.031, 95% CI 1.058-3.898). AMCc could be a better prognostic factor than Pre-AMC in patients with ESCC. AMCc decrease predicts worse OS and DFS in ESCC undergoing curative resection.
在食管鳞状细胞癌中，术前绝对单核细胞计数（Pre-AMC）升高被报道为生存的预测指标，但术后绝对单核细胞计数变化（AMCc）的临床应用仍不清楚。本研究旨在探讨 AMCc 在 ESCC 中的预后价值。纳入了 686 例接受根治性手术且无术前辅助治疗的 ESCC 患者。在手术前一周和手术后一周内记录 Pre-AMC 和 AMCc。我们以 Pre-AMC 的中位数为最佳截断值来评估 Pre-AMC 与患者生存之间的关系。AMCc 定义为 AMCc 升高（高于 Pre-AMC）和 AMCc 降低（低于 Pre-AMC）。对人口统计学和临床特征、无病生存率（DFS）和总生存率（OS）进行了统计学分析。多因素分析显示，AMCc 是 OS（P = 0.002，HR = 0.614，95%CI 0.450-0.837）和 DFS（P = 0.023，HR = 0.656，95%CI 0.456-0.943）的更好独立预后因素，而 Pre-AMC 仅是 OS 的独立预后因素（P = 0.033，HR = 2.031，95%CI 1.058-3.898）。AMCc 可能是 ESCC 患者比 Pre-AMC 更好的预后因素。AMCc 降低预示着接受根治性切除的 ESCC 患者的 OS 和 DFS 更差。
